The global allergy immunotherapy market was valued at USD 1.70 billion in 2023 and is projected to grow from USD 1.84 billion in 2024 to USD 4.02 billion by 2032, reflecting a CAGR of 10.3% over the forecast period (2024-2032). In 2023, Europe led the market, accounting for a 70.59% share.
The allergy immunotherapy market is witnessing steady growth, driven by the rising prevalence of allergic disorders worldwide and the increasing demand for long-term treatment options that go beyond symptomatic relief. Allergy immunotherapy, including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), offers disease-modifying benefits by addressing the underlying causes of allergies, such as pollen, dust mites, animal dander, and other allergens. Growing awareness among patients and healthcare providers about the efficacy and safety of immunotherapy, coupled with advancements in biologics and personalized treatment approaches, is fueling market expansion. Additionally, supportive government initiatives, improved healthcare infrastructure, and increasing investments in research and development are expected to further accelerate adoption. However, factors such as treatment costs, lengthy therapy duration, and limited awareness in developing regions remain challenges for market growth.
Market Segmentation:
The allergy immunotherapy market is segmented by type into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). SCIT dominated in 2023 due to its high efficacy and ongoing product launches, such as Stallergenes Greer’s relaunch of Alustal in Spain and Italy (June 2021). SLIT is expected to grow significantly due to rising adoption and regulatory approvals, including ALK’s FDA-approved ODACTRA (January 2023). By indication, allergic rhinitis leads the market, driven by increasing cases and product launches like ALK’s expanded approval for Ragwitek (April 2021). A strong pipeline, such as ALK’s Phase 3 ACARIZAX trial (June 2023), further supports growth. The allergic asthma and other allergies segment, including food allergies, is also set for expansion due to rising R&D investments and regulatory approvals, such as the FDA’s approval of Xolair for food allergies (February 2024). By distribution channel, retail and online pharmacies hold the largest share due to convenience and discounts, while hospital pharmacies are growing due to rising allergy-related admissions. Reports from Anaphylaxis UK (September 2022) highlight increasing hospitalizations, reinforcing the market’s upward trajectory.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/allergy-immunotherapy-market-100727
List Of Key Companies In Allergy Immunotherapy Market:
ALK (Denmark)
Stallergenes Greer (Switzerland)
Allergy Therapeutics (U.K.)
HAL Allergy B.V. (Netherlands)
HollisterStier Allergy (U.S.)
Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China)
LETIPharma (Spain)
Dermapharm Holding SE (Germany)
Market Growth:
Allergic conditions negatively impact an individual’s quality of life by impairing various physiological functions. The increasing prevalence of allergies worldwide, driven by greater exposure to allergens like pollen, dust mites, and mold, is fueling the demand for effective treatments such as allergy immunotherapy (AIT). Allergies are rising rapidly in both developing and Western countries, boosting the adoption of immunotherapy. According to the CDC, in 2023, approximately 31.8% of U.S. adults suffered from allergies, with 25.7% affected by seasonal allergies. Similar trends are expected globally, further driving demand for AIT. Additionally, government initiatives and industry efforts to raise awareness and develop innovative treatments are supporting market growth. For example, in November 2021, Canada-based Angany partnered with Nextmune, a division of Vimian Group, to develop new allergy and atopic dermatitis vaccines.
Market Restraining Factors:
Despite the benefits of allergy immunotherapy, adherence remains low due to factors like limited patient awareness and inadequate reimbursement. According to a 2022 NCBI article, the inconvenience of SCIT and adverse effects of both subcutaneous and sublingual therapies are key reasons for treatment discontinuation. Additionally, high costs pose a barrier, with allergy shots in the U.S. ranging from USD 1,600 to USD 4,000 annually without insurance and around USD 800 with coverage. Furthermore, SLIT drops remain unapproved and uninsured in the country. The high treatment costs and limited insurance coverage in some regions continue to hinder the adoption of allergy immunotherapy.
Regional Insights:
Europe led the allergy immunotherapy market in 2023 with USD 1.20 billion in revenue and is expected to dominate throughout the forecast period, driven by rising allergy prevalence, government initiatives, and strong R&D investments. For example, Stellargenes Greer launched Orylmyte in Belgium (November 2021). The Asia Pacific is projected to grow at the highest CAGR, supported by increasing allergy cases, expanding market presence of key players, and rising awareness, as seen in ALK-Abello’s regulatory submission in China (March 2022). North America is set for significant growth due to higher treatment rates, novel therapy adoption, and industry expansion efforts. Meanwhile, Latin America and the Middle East & Africa, though holding smaller market shares in 2023, are expected to grow steadily with government initiatives and increased funding for product development.